The spin-off of the University of Valencia, located in the Science Park of the academic institution, develops biotechnological solutions for the prevention, diagnosis and treatment of resistant pathogenic bacteria, with a methodology based on phages and from the One Health global approach
EVOLVING THERAPEUTICS was born as a spin-off of the University of Valencia, located in the Science Park of the academic institution, with the aim of transferring to the market a customized system for isolation of environmental bacteriophages aimed at tackling the problem of antimicrobial resistance. In recognition of its work during its first four months of operation, the VII National Congress of Entrepreneurial Scientists recognized the young company with the award for 'the startup with the greatest impact'.
The congress, held in Murcia under the slogan 'Entrepreneurship is not science fiction', awarded the Valencian company, which stood out during the first startup competition of the event. In this regard, Marisa Domingo Calap, CEO of the company, acknowledged that "this award is very important as recognition of the day-to-day work, as well as the company's commitment to society". She also emphasized that this award has allowed them "to make themselves known, and being a recently created spin-off with a small portfolio of clients, this is something very valuable as it opens the door to potential clients".
The prize consisted of a tablet valued at 1,000 euros and 500 euros as a gift from the DRO Foundation; mentoring and editing of a video, along with a ticket for each winning company to attend the Waykup event, both courtesy of UCAM HITECH, in which more than 100 national and international investors will participate, "something very important at the point where the company is in search of funding".
"This award is very important to us as a recognition of the work we carry out every day, as well as our commitment to society," Marisa Domingo Calap, CEO of Evolving Therapeutics
"It is important to attend this kind of forums, because on the one hand you can share experiences, concerns and expectations with people who have been in the same situation we are in right now; and on the other hand where there are investors very interested in technology-based companies such as ours," said the CEO of EVOLVING, while noting, "for the moment, we have the support of the Respiralia Foundation, a non-profit organization for cystic fibrosis, which has made us a financial contribution of 180. 180,000, which has allowed us to set up our first laboratory and start providing services".
As for the present, Domingo Calap highlighted that "currently and in only 4 months operating, we have invoiced more than €45,000, exceeding the income forecast for this 2023 reflected in our business plan, and we expect to exceed €100,000 of income at the end of the year". On the other hand, in reference to the next steps of the startup, she pointed out that "right now we are looking for an investment of €2M to set up a GMP - BSL2 clean room, which will allow us to produce therapeutic vials for the compassionate treatment of patients affected by multidrug-resistant bacteria as well as the execution of a clinical trial. This will also allow us to internationalize our services".
"We are currently seeking investment of 2 million euros to set up a GMP - BSL2 clean room, which will allow us to produce therapeutic vials for the compassionate treatment of patients affected by multidrug-resistant bacteria as well as the execution of a clinical trial. This will also enable us to internationalize our services"
Winner of the VIII VLC/STARTUP Awards
In the last edition of the VLC/STARTUP Awards, an initiative of the University of Valencia Science Park Foundation (FPCUV) for the support program for innovative companies, framed in a collaboration agreement signed between the Universitat de València and Banco Santander with the aim of promoting and supporting the creation and consolidation of companies in the university environment of innovation, EVOLVING THERAPEUTICS was awarded in the Laboratory modality, a category that includes a financial endowment of 3. 3,000 euros and the assignment of a laboratory space at the Parc Científic free of charge for one year.